Novartis Alcon Has Part Win Part Loss On Patanol Patent
Novartis had a good day in the Federal Circuit Court of Appeals this week. It’s Alcon unit successfully fought off Apotex Inc. from marketing a generic version of the drug, Patanol. The Patanol patent expires in 2015 and until then, Apotex is not allowed to sell the eye medication. While Federal Circuit invalidated some parts of the patent, it held other aspects of the patent valid. Under the obviousness test, the court essentially asks whether the invention was obvious, in light of the information known to a “person having ordinary skill in the art....